Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

June 5, 2001 5 June, 2001

Pheromone Sciences appoints Chief Financial Officer

Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Mr. Larry Cooper C.A. as its Chief Financial Officer.

A Chartered Accountant and member of the both the Order of Chartered Accountants and the Canadian Institute of Chartered Accountants, Mr. Cooper brings an enviable mix of financial and business development experience to the Company. Most recently, Mr. Cooper served as the Chief Financial Officer and Chief Administrative Officer of The Canadian Institute, an international business service provider with offices located in London, New York & Toronto.

Prior thereto, he spent ten years (1988-1998) with Allergan Canada a multi-national pharmaceutical manufacturer of prescription and non- prescription healthcare products. During this timeframe Mr. Cooper spent the first six years as Chief Financial Officer and thereafter as both the Chief Financial Officer and the Director of Business Development

Additional experience includes financial roles at Spalding Canada (1984--1988) where he was Chief Financial Officer, United Tire and Rubber Company (1982- -1984) and as the Accounting Manager at ENS Biologicals Inc. Mr. Cooper received his Bachelor of Commerce (Honors) degree from The University of Toronto.

In commenting on the announcement, Mr. Neuman CEO said "Mr. Cooper's experience is ideally suited to the further development and implementation of Pheromone Sciences Corp's business strategy. We are delighted to have Larry join our team."

Mr. Cooper succeeds Mr. Barry Sadrehashemi C.A., who has faithfully and efficiently served Pheromone Sciences from his Calgary base during the Company's transition to a public entity and subsequent move to Toronto.


Lorne Woods 1-(800) 937-3095

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.